ATE389724T1 - Menschliche dnase i hyperaktive varianten - Google Patents

Menschliche dnase i hyperaktive varianten

Info

Publication number
ATE389724T1
ATE389724T1 AT97929686T AT97929686T ATE389724T1 AT E389724 T1 ATE389724 T1 AT E389724T1 AT 97929686 T AT97929686 T AT 97929686T AT 97929686 T AT97929686 T AT 97929686T AT E389724 T1 ATE389724 T1 AT E389724T1
Authority
AT
Austria
Prior art keywords
variants
human dnase
hyperactive
hyperactive variants
relates
Prior art date
Application number
AT97929686T
Other languages
English (en)
Inventor
Robert LAZARUS
Clark Pan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389724T1 publication Critical patent/ATE389724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97929686T 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten ATE389724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/663,831 US6391607B1 (en) 1996-06-14 1996-06-14 Human DNase I hyperactive variants

Publications (1)

Publication Number Publication Date
ATE389724T1 true ATE389724T1 (de) 2008-04-15

Family

ID=24663430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929686T ATE389724T1 (de) 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten

Country Status (12)

Country Link
US (4) US6391607B1 (de)
EP (1) EP0910647B1 (de)
JP (1) JP3468778B2 (de)
AT (1) ATE389724T1 (de)
AU (1) AU737618B2 (de)
CA (1) CA2257133C (de)
DE (1) DE69738581T2 (de)
DK (1) DK0910647T3 (de)
ES (1) ES2301180T3 (de)
NZ (1) NZ333128A (de)
PT (1) PT910647E (de)
WO (1) WO1997047751A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050016668A1 (en) * 2003-06-16 2005-01-27 Lori Powers Method and apparatus for cutting through an outer layer on a container
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2005007187A1 (en) * 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2269359C2 (ru) * 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
EP1880733A4 (de) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Verfahren zur verlängerung der lebensdauer eines menschen und von tieren
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
CN101563134A (zh) 2006-10-18 2009-10-21 派利尼斯有限公司 用于诊断和治疗男性低生育力的方法和药物组合物
JP5372769B2 (ja) * 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
WO2010117901A1 (en) * 2009-04-10 2010-10-14 Bio-Rad Laboratories, Inc. Modified dnase compositions and methods of use thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
LT2496691T (lt) 2009-11-02 2017-06-12 University Of Washington Terapinės nukleazės kompozicijos ir būdai
US9102949B2 (en) 2010-04-23 2015-08-11 University Of Massachusetts CNS targeting AAV vectors and methods of use thereof
EP2468870A1 (de) 2010-12-23 2012-06-27 Philip Morris Products S.A. Verfahren zur Expression von Desoxyribonuklease in Pflanzen
HRP20180564T1 (hr) 2011-04-29 2018-06-01 University of Washington, UW Center for Commercialization Terapijski pripravci nukleaze i postupci
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
EP3063275B1 (de) 2013-10-31 2019-09-25 Resolve Therapeutics, LLC Therapeutische nuklease-albumin-fusionen und verfahren
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CA2964272A1 (en) 2014-10-21 2016-04-28 Guangping Gao Recombinant aav variants and uses thereof
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
BR112017014433A2 (pt) * 2015-01-04 2018-05-15 Protalix Ltd. proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
US20180214576A1 (en) * 2015-07-28 2018-08-02 University Of Massachusetts Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
EP3351263A1 (de) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmazeutische zusammensetzung zur behandlung oder prävention von gewebeadhäsion
KR102806169B1 (ko) 2017-08-18 2025-05-13 뉴트롤리스 인코포레이티드 조작된 dnase 효소 및 치료에의 사용
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
AU2019209770B2 (en) * 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2020142740A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
EP4055156A2 (de) * 2019-11-08 2022-09-14 Thermo Fisher Scientific Baltics Uab Desoxyribonuklease-varianten und verwendungen davon
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
EP4225903A1 (de) 2020-10-07 2023-08-16 Protalix Ltd. Langwirkende dnase
EP4294827A1 (de) 2021-02-19 2023-12-27 Theripion, Inc. Paraoxonasefusionspolypeptide sowie zugehörige zusammensetzungen und verfahren
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
AU5546494A (en) 1992-11-02 1994-05-24 Genentech Inc. Compaction assay for assessment of respiratory disease therapy
HU223272B1 (hu) 1995-02-24 2004-04-28 Genentech Inc. Humán dezoxiribonukleáz I variánsok
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants

Also Published As

Publication number Publication date
DE69738581D1 (de) 2008-04-30
US7407785B2 (en) 2008-08-05
DK0910647T3 (da) 2008-07-21
JP3468778B2 (ja) 2003-11-17
EP0910647A1 (de) 1999-04-28
US20080293121A1 (en) 2008-11-27
US20050170365A1 (en) 2005-08-04
AU3368497A (en) 1998-01-07
CA2257133C (en) 2008-01-22
DE69738581T2 (de) 2009-04-23
WO1997047751A1 (en) 1997-12-18
EP0910647B1 (de) 2008-03-19
US20020173025A1 (en) 2002-11-21
NZ333128A (en) 2000-08-25
JP2000512496A (ja) 2000-09-26
PT910647E (pt) 2008-04-15
US6391607B1 (en) 2002-05-21
ES2301180T3 (es) 2008-06-16
AU737618B2 (en) 2001-08-23
CA2257133A1 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
ATE330967T1 (de) An her2 bindende peptidverbindungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE231852T1 (de) Bicyclische aromatische verbindungen
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE69529235D1 (de) Menschliche dnase i varianten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE278011T1 (de) Human dnase ii
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
MX9706429A (es) Variantes de dnasa i humana.
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910647

Country of ref document: EP